Novomer, Inc.

Novomer Recognized by AlwaysOn as GoingGreen Top 100 Winner

Novomer Recognized by AlwaysOn as GoingGreen Top 100 Winner

September 15, 2008

BOSTON - (Business Wire) Novomer Inc., a materials company pioneering a family of high-performance, biodegradable plastics, polymers and other chemicals from renewable substances, today announced that it has been honored by AlwaysOn as one of the GoingGreen Top 100 Winners. Novomer was selected by the AlwaysOn editorial team and other industry experts spanning the globe, based on a set of five criteria: innovation, market potential, commercialization, stakeholder value and media buzz.

AVEO Pharmaceuticals, Inc.

AVEO Pharmaceuticals Initiates First Clinical Trial of Novel HGF Antagonist in Patients with Advanced Solid Tumors and Lymphomas

AVEO Pharmaceuticals Initiates First Clinical Trial of Novel HGF Antagonist in Patients with Advanced Solid Tumors and Lymphomas

September 23, 2008

SCH900105 (AV-299) Marks First of Several Monoclonal Antibodies from AVEO’s Discovery Platform; Trial Triggers Milestone Under Agreement with Schering Plough

Concert Pharmaceuticals, Inc.

Concert Pharmaceuticals Presents Preclinical Results Supporting Co-Administration of CTP-347 and Tamoxifen

Concert Pharmaceuticals Presents Preclinical Results Supporting Co-Administration of CTP-347 and Tamoxifen

September 25, 2008

Results Presented at the North American Menopause Society’s 2008 Annual Meeting

Quanterix Corporation

Quanterix Corporation Awarded $185,000 Grant from the National Cancer Institute

Quanterix Corporation Awarded $185,000 Grant from the National Cancer Institute

September 30, 2008

Leader in single molecule protein detection will utilize funds to develop single molecule arrays for the detection of low abundance cancer proteins

Concert Pharmaceuticals, Inc.

Steven Bernitz Joins Concert Pharmaceuticals as Chief Business Officer

Steven Bernitz Joins Concert Pharmaceuticals as Chief Business Officer

October 6, 2008

Lexington, MA (October 6, 2008) – Concert Pharmaceuticals, Inc. today announced that Steven B. Bernitz has joined the company as its Senior Vice President and Chief Business Officer. In this role, he will be a member of Concert’s executive management team, designing and implementing strategic planning initiatives and having overall responsibility for Concert’s business development activities. Mr. Bernitz replaces Jeffrey Williams who now serves as a consultant to the company.

Mascoma Corporation

Mascoma Corporation Announces $49.5 Million in DOE and State of Michigan Funding for Cellulosic Fuel Facility

Mascoma Corporation Announces $49.5 Million in DOE and State of Michigan Funding for Cellulosic Fuel Facility

October 7, 2008

Funds will accelerate path to commercialization

BOSTON, MA – October 7, 2008: Mascoma Corporation, with the U.S. Department of Energy (DOE), Michigan Governor Jennifer M. Granholm, members of the Michigan Congressional delegation and the Michigan Economic Development Corporation, today announced that Mascoma has received a total of $26.0 million in funding from the DOE and an overall contribution of $23.5 million from the State of Michigan.

LS9

LS9, Inc. Appoints Bill Haywood Chief Executive Officer

LS9, Inc. Appoints Bill Haywood Chief Executive Officer

October 8, 2008

SOUTH SAN FRANCISCO, Calif., Oct. 8 /PRNewswire/ -- LS9, Inc., the
Renewable Petroleum Company(TM), today announces it has appointed Bill
Haywood as Chief Executive Officer. Mr. Haywood brings over 30 years of
experience in the fuels manufacturing business and a proven track record of
planning, engineering, execution and start-up of major projects within the
energy sector.

"The coming year will be pivotal to LS9 as the company delivers
significant achievements in the development of second-generation biofuels,"

T2 Biosystems, Inc.

T2 Biosystems Announces Strategic Investment and Technology Development Agreement with In-Q-Tel

T2 Biosystems Announces Strategic Investment and Technology Development Agreement with In-Q-Tel

October 17, 2008

Strategic Partnership with In-Q-Tel Brings Portable, Laboratory-Quality Diagnostics to the U.S. Intelligence Community

T2 Biosystems, Inc.

T2 Biosystems Raises $10.8 Million in Series B Financing

T2 Biosystems Raises $10.8 Million in Series B Financing

October 17, 2008

Industry Leader Stan Lapidus Joins Board of Directors

CAMBRIDGE, Mass.--(BUSINESS WIRE)--T2 Biosystems, Inc., a company developing the first portable medical diagnostic products which combine nanotechnology and miniaturized magnetic resonance (MR) technology, today announced that it has raised $10.8 million in a Series B financing. Proceeds from the financing will be used to accelerate the development of T2 Biosystems’ revolutionary rapid diagnostic platform.

T2 Biosystems, Inc.

T2 Biosystems Appoints Pamela Weagraff as Vice President, Regulatory and Quality

T2 Biosystems Appoints Pamela Weagraff as Vice President, Regulatory and Quality

October 20, 2008

CAMBRIDGE, Mass.--(BUSINESS WIRE)--T2 Biosystems, Inc., a company developing the first portable medical diagnostic products which combine nanotechnology and miniaturized magnetic resonance (MR) technology, today announced the appointment of Pamela J. Weagraff, RAC to the newly created position of Vice President, Regulatory and Quality.